TABLE 3 Biogen Idec Inc. June 30, 2006

Condensed Consolidated Statements Of Income - Non-GAAP (in millions, except per share amounts)

Three Months Ended

Six Months Ended

	June 30,		June 30,	
EARNINGS (LOSS) PER SHARE	2006	2005	2006	2005
GAAP Earnings (loss) per share - Diluted Adjustment to Net Income (loss) (as detailed below) Non-GAAP Earnings per share - Diluted	\$ (0.50) 1.06 \$ 0.57	\$ 0.10 0.33 \$ 0.43	\$ (0.14) 1.26 \$ 1.11	\$ 0.23 0.50 \$ 0.73
An itemized reconciliation between net income (loss) on a GAAP basis and net income on a non-GAAP basis is as follows:				
GAAP Net Income (loss)	\$ (170.6)	\$ 34.5	\$ (47.6)	\$ 78.0
Adjustments:				
COGS: Fair value step up of inventory acquired from former Biogen, Inc.	0.9	9.0	4.9	18.3
COGS: Stock option expense	0.1	-	0.1	-
R&D: Costs associated with sale of Oceanside Manufacturing Facility	-	1.9	-	1.9
R&D: Severance and restructuring	0.3	-	0.3	-
R&D: Stock option expense	6.4	-	11.2	-
SG&A: Merger related and purchase accounting costs	0.1	-	0.1	0.4
SG&A: Severance and restructuring	0.9	-	1.6	-
SG&A: Stock option expense	8.3	-	16.6	-
Purchase accounting: Amortization of acquired intangible assets related to the merger with former Biogen, Inc.	76.3	77.1	147.0	152.8
Purchase accounting: In-process research and development related to the acquisition of Conforma Therapeutics Corporation and Fumapharm AG	330.5	-	330.5	-
Purchase accounting: Gain on settlement of license agreement with Fumapharm AG	(34.2)	-	(34.2)	-
Impairment and loss on sale of long lived assets	(0.8)	75.6	(1.1)	75.6
Income taxes: Income tax effect of reconciling items	(20.9)	(49.0)	(39.3)	(72.1)
Cumulative effect of accounting change from adoption of FAS123R, net of income tax	-	-	(3.8)	-
Non-GAAP Net Income	\$ 197.3	\$ 149.0	\$ 386.4	\$ 254.8

Numbers may not foot due to rounding.

Shares used in calculating adjustments to net loss and diluted non-GAAP earnings per share are 348,730,000 and 348,222,000 for the three and six months ended June 30, 2006, respectively.

The non-GAAP financial measures presented in this table are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Management uses these measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in the Company's business over time. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures.